Pfizer Inc. (PFE)
Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
Pfizer said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. The hemophilia A treatment could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.
Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial
Pfizer said on Wednesday that its gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment.
Earnings Preview: Pfizer (PFE) Q2 Earnings Expected to Decline
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
Pfizer and Roche don't have any anti-obesity medicines marketed yet. Both are trying to change that as fast as possible.
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
Pfizer doesn't currently produce any anti-obesity medicines, but it wants to do so. However, its most mature program on that front isn't exactly a sizzler.
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Inc PFE, one of the world's largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.
Wall St Veteran Names Worst Value Trap in the World
Lee and I have a list of stocks we love to hate, and one of Lee's picks is Pfizer (NYSE: PFE).
Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason
Israel's CytoReason, which uses AI to develop disease models, said on Wednesday it had raised $80 million in a private funding round.
European Commission didn't provide enough information about COVID-19 vaccine deals, EU court says
The European Commission did not allow the public enough access to information about COVID-19 vaccine purchase agreements it secured with pharmaceutical companies during the pandemic, the EU general court said Wednesday.
Forget Medical Properties Trust: This High-Yielding Dividend Stock Is a Much Better Buy
Medical Properties Trust pays investors a high yield, but the stock carries significant risk. Pfizer's more modest yield of 6% is still well above average, and the dividend has been increasing in recent years.
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Pfizer (PFE) reachead $29.10 at the closing of the latest trading day, reflecting a +0.62% change compared to its last close.
